comparemela.com

Jan Koch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REDCARE PHARMACY : Deutsche Bank keeps its Buy rating

In a research note published by Jan Koch, Deutsche Bank advises its customers to buy the stock. The target price is unchanged at EUR 178.

Jan kochDeutsche bank

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions

EINDHOVEN, the Netherlands, May 02, 2024 ONWARD Medical N.V. , a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence.

United statesNoord hollandKhaled bahiAditi royJan kochEngineering centerVp communicationsInternational financial reporting standardsAdoption of the companyNetherlands authority for the financial marketsNeither the companyDrug administrationAmendment of the companyInstruction to ernst young accountantsGeneral meetingNetherlands authority

STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank reiterates its Neutral rating

In a research note published by Jan Koch, Deutsche Bank gives a Neutral rating to the stock. The target price is unchanged at EUR 40.

Jan kochDeutsche bank

REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating

Deutsche Bank analyst Jan Koch maintains his Buy rating on the stock. The target price is still set at EUR 178.

Jan kochDeutsche bank

DOCMORRIS : Deutsche Bank remains its Buy rating

In a research note, Deutsche Bank analyst Jan Koch has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at CHF 110.

Jan kochDeutsche bank

vimarsana © 2020. All Rights Reserved.